Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension

Next Previous
X
Search
Trial Profile

A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Macitentan (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms SERAPHIN
  • Sponsors Actelion Pharmaceuticals

    • Most Recent Events

    • 24 May 2023 Results of meta analysis (n=1982 from 3 studies NCT01106014 , NCT00660179 and NCT00303459) assessing Outcomes in Patients With Pulmonary Arterial Hypertension (PAH) Associated With Congenital Heart Disease (CHD) Receiving PAH Medication presented at the 119th International Conference of the American Thoracic Society
    • 01 Aug 2022 Results assessing adjusting overall survival estimates of macitentan in pulmonary arterial hypertension after treatment switching, published in the Advances in Therapy.
    • 12 Jul 2022 Results published in the Advances in Therapy

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top